With close to one million downloads, Shotsy is the most popular GLP-1 tracking app on the market, and now meets patients at ...

Latent Health is tapping into the $200 billion market for specialty drugs with AI agents that help doctors convince insurers ...

Hello, and welcome to Health Brief. While Republicans in the House are sussing out which policies they want to grab from the ...

The TrumpRx website claims to offer the best prices for medications. Here’s where Americans still pay more — and much more.

The Pennsylvania Department of Drug and Alcohol Programs (DDAP) this week launched “Narcan in Courts” — a new initiative to ...

Internal reports regarding the action taken against drugs and organised crime prepared by the Ludhiana police and of districts leading in the state’s average on various paramete ...

Pharma regulations in China, India, Turkey, and elsewhere mean that Novo Nordisk’s patent on the drug expires this week.

Scottish Government announces its “Preventing Harm, Promoting Recovery” - hoping to turn our European-worst record in drug ...

Despite being first to launch a GLP-1 drug for weight loss, Novo's market share has eroded, and the company now only captures about 40% of the market.

The entry of generic versions of semaglutide is set to dramatically change India's healthcare landscape. Experts suggest prices could fall by 60–70%, bringing monthly treatment costs down from ₹10,000 ...

While the introduction of branded generics is likely to accelerate volumes for GLP-1 agonists, value growth may moderate because of price erosion.

The Ozempic Effect originally premiered in 2025, but only landed on Netflix UK last Friday (February 27). It explores the use of GLP-1 drugs for weight management and how they are reshaping the ...